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Cycle 1 in this study. Adverse events (AEs) were reported 
in all 15 patients. Most common AEs (>30 %) were hyper-
lipasemia (47 %), hyperamylasemia (40 %), and consti-
pation (33 %). Acute pancreatitis (Grades 2 and 3) and 
pancreatitis (Grade 1) were complicated in three patients 
during the study. Dose-dependent increase in plasma orte-
ronel concentrations was indicated over the 200–400 mg 
BID dose range. Prednisolone coadministered did not alter 
PK of orteronel. Serum testosterone was rapidly suppressed 
below the lower limit of quantification across all doses. Of 
15 subjects, 13 achieved at least a 50 % reduction from 
baseline in prostate-specific antigen.
Conclusions Orteronel at doses up to 400 mg BID was 
tolerable in Japanese CRPC patients. The present results 
support further evaluation of orteronel with or without 
prednisolone.
Keywords Orteronel · Castration-resistant prostate 
cancer · 17,20-Lyase inhibitor · Phase 1
Introduction
Prostate cancer is the second most common cancer in men 
worldwide [1]. In Japan, the number of patients with pros-
tate cancer is rapidly increasing because of the aging of the 
population, westernization of dietary habits, and advances 
in diagnostic techniques. The incidence of the malignancy 
is estimated at 15.1 per 100,000 patients (age-standardized 
rate) [1].
Castration by orchidectomy or treatment with agonists 
of receptors for gonadotropin-releasing hormone (GnRH), 
also known as luteinizing hormone-releasing hormone 
(LH-RH), has been the standard of care in advanced pros-
tate cancer. Patients with prostate cancer that has recurred 
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Purpose Orteronel (TAK-700) is a non-steroidal, selec-
tive, reversible inhibitor of 17,20-lyase. We evaluated the 
safety, tolerability, pharmacokinetics, pharmacodynamics, 
and antitumor effect of orteronel with or without predniso-
lone in Japanese patients with castration-resistant prostate 
cancer (CRPC).
Methods We conducted a phase 1 study in men with pro-
gressive and chemotherapy-naïve CRPC. Patients received 
orteronel orally at doses of 200–400 mg twice daily (BID) 
with or without oral prednisolone (5 mg BID). Dose-limit-
ing toxicity (DLT) was assessed during Cycle 1 (28 days). 
Patients could continue study treatment until any of crite-
ria for treatment discontinuation were met. Gonadotropin-
releasing hormone therapy was continued in patients with-
out prior orchidectomy.
Results Fifteen patients were enrolled and administered at 
least one dose of orteronel. No DLTs were reported during 
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after local therapy or has distantly disseminated usually 
respond to androgen deprivation therapy (ADT); however, 
most patients eventually experience disease progression 
within a median of 18–24 months [2].
The intra-prostatic synthesis of testosterone from adre-
nal-derived precursors likely accounts for the relatively 
high testosterone levels in the prostate after ADT [3] and 
castration-resistant prostate cancer (CRPC) cells express all 
necessary enzymes for the de novo synthesis of dihydrotes-
tosterone [4]. CYP17A1 is a key enzyme in the generation 
of androgens and estrogens in the adrenal glands and tumor 
tissue, and it catalyzes two independently regulated steroid 
reactions, involving 17α-hydroxylase and 17,20-lyase in the 
biosynthesis pathway [5]. This finding led to the concept of 
CYP17A1 inhibition for depleting both intra-tumoral and 
extragonadal sources of steroid ligands [5–9]. The impor-
tance of this pathway in CRPC has been supported by posi-
tive results in phase 3 trials with abiraterone acetate (Zyt-
iga®) [10, 11]. However, toxicities attributed to a syndrome 
of secondary mineralocorticoid excess have been observed 
with abiraterone, and coadministration of a mineralocor-
ticoid receptor antagonist or glucocorticoid is required to 
suppress adrenocorticotropic hormone (ACTH) levels [12].
Orteronel (TAK-700) is a non-steroidal, selective, 
reversible inhibitor of 17,20-lyase. It inhibited 17,20-
lyase activity 5.4-fold more potently than it suppressed 
17-hydroxylase activity in cell-free enzyme assays, sug-
gesting that orteronel treatment results in the inhibi-
tion of androgen synthesis with only partial inhibition of 
17α-hydroxylase activity, which allows adrenal cortisol 
synthesis to continue. Preclinical studies revealed that orte-
ronel reduced serum androgen levels in vivo in monkeys 
[13]. By selectively inhibiting the extragonadal synthesis 
of androgens in either the adrenal cortex or prostate tumor 
cells, orteronel may represent a new therapeutic option for 
patients with CRPC. The relative selectivity of orteronel for 
17,20-lyase may also offer benefits compared with other 
therapies that target androgen synthesis accompanied by 
decreased requirements for concurrent administration of 
steroids such as prednisolone.
This is the first clinical report to evaluate the safety, tol-
erability, pharmacokinetics (PK), pharmacodynamics (PD), 
and efficacy of orteronel based on the findings of a phase 1 
study in Japanese patients with chemotherapy-naïve CRPC.
Patients and methods
Patients
Patients were recruited from three centers in Japan. The study 
was conducted in accordance with the Declaration of Hel-
sinki/Good Clinical Practices. The Institutional Review Board 
approved all aspects of the study, and all participants provided 
written informed consent. The eligibility criteria included his-
tologically or cytologically confirmed prostate adenocarci-
noma, prostate-specific antigen (PSA) levels of ≥2 ng/mL at 
screening, an increase from nadir in PSA levels in ≥2 succes-
sive measurements by the time of screening, well-controlled 
castration (serum testosterone level <0.5 ng/mL), an Eastern 
Cooperative Oncology Group (ECOG) performance status 
of 0–2 at screening, and adequate liver, renal, and bone mar-
row functions. Patients were also required to discontinue all 
antiandrogen therapy for at least 6 (bicalutamide) or 4 weeks 
(any other therapy) before the first dose of orteronel. Patients 
with an unacceptable cardiac complication were excluded. 
Patients who had received prior chemotherapy for prostate 
cancer were also excluded. Eligibility did not require a deter-
mination of the presence or absence of metastasis.
Study design
This was a phase 1, open-label, multiple-dose study in 
Japanese patients with chemotherapy-naïve, hormone 
therapy-resistant prostate cancer (also known as CRPC). 
For patients who had not undergone prior orchidectomy, 
the castrated testosterone level was maintained by GnRH 
therapy. The primary objective of this study was to assess 
the safety, tolerability, and PK of orteronel as a single 
agent or in combination with prednisolone in patients with 
CRPC. The secondary objective was to determine the PD 
and antitumor effect of orteronel using serum PSA levels, 
PSA response rates, and objective disease response rates in 
patients with CRPC [14].
Patients received orteronel orally either with or with-
out oral prednisolone at the following doses: 200 mg twice 
daily (200-mg BID cohort), 400 mg BID (400-mg BID 
cohort), or 400 mg BID plus prednisolone 5 mg BID (400-
mg BID plus prednisolone cohort). The propriety of transi-
tions to subsequent dose cohort was judged on the basis of 
the number of patients with dose-limiting toxicities (DLTs) 
during Cycle 1 (28 days). Furthermore, additional two 
cohorts in which subjects received orteronel 300 mg BID 
(300-mg BID cohort) or orteronel 300 mg BID plus pred-
nisolone 5 mg BID (300-mg BID plus prednisolone cohort) 
were assessed on the basis of a preliminary interim analy-
sis. Patients could continue study treatment until criteria for 
treatment discontinuation were met. The use of aldoster-
one antagonists (e.g., eplerenone) was allowed for patients 
with clinical symptoms of mineralocorticoid excess such as 
hypertension, hypokalemia, and edema.
Assessments
Safety assessments included the evaluation of adverse events 
(AEs), laboratory profiles, physical examination, and vital 
375Cancer Chemother Pharmacol (2015) 75:373–380 
1 3
signs throughout the study. AEs were graded using National 
Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) v3.0. Analysis of serum amylase and 
lipase was added to the clinical laboratory tests before enroll-
ment of patients into the 400-mg BID plus prednisolone 
cohort because pancreatitis was reported during the study. 
A safety follow-up was performed for 28 days after the final 
dose of the study treatment. During Cycle 1 (28 days), DLT 
was also evaluated. DLTs were defined as any drug-related AE 
of ≥ Grade 3 and pre-specified cardiac-related AEs of lower 
grade. Hypertension, hypokalemia, and edema attributed to 
increased ACTH secretion maintained at Grade 2 or lower 
through the use of eplerenone were not considered DLTs.
The pharmacokinetic endpoints were to evaluate PK 
profiles in plasma and urinary excretion of unchanged orte-
ronel and a primary metabolite (M-I). Unchanged orteronel 
and M-I in plasma and urine were determined by the vali-
dated high-performance liquid chromatography–tandem 
mass spectrometry.
Endocrine parameters such as serum testosterone and 
dehydroepiandrosterone sulfate (DHEA-S) were measured 
for PD analysis. The blood sample were collected on Days 
1, 8, 15, and 22 of Cycle 1 and then on Day 1 of each sub-
sequent 28-day cycle. Assay procedure for testosterone was 
improved during the study, and the lower limit of quanti-
fication (LLOQ) for testosterone changed from 0.05 to 
0.03 ng/mL.
The efficacy endpoints were serum PSA levels, PSA 
response rates based on the Prostate Cancer Clinical Tri-
als Working Group (PCWG) 2 criteria, and objective dis-
ease response rates based on the General Rule for Clinical 
and Pathological Studies on Prostate Cancer and modified 
RECIST version 1.0. PSA levels were measured on Days 
1 and 15 in Cycle 1, on Day 1 of Cycle 2 and each sub-
sequent cycle. Tumor assessments were performed on Day 
29, 85, and every 12-week cycle for subsequent cycles.
Statistical analysis
Three patients (a maximum of six patients) were to be 
included in each cohort. The number of patients was deter-
mined according to the “Guidelines on clinical evaluation 
method of antineoplastics” in Japan (PFSB/ELD, 2005) 
[15], and the setting was not based on the statistical ration-
ale. Standard summary statistics were used for safety, PK, 
PD, and efficacy analyses.
Results
Patients and exposure
Between April 2010 and January 2012, 15 patients (3 in 
each cohort) were enrolled in this study. All 15 patients 
received at least one dose of orteronel. At the time of 
analysis, 13 patients had discontinued orteronel treatment 
because of the following reasons: lack of efficacy in eight 
patients and TEAEs in five patients. The remaining two 
patients were under treatment: One patient in the 200-mg 
BID cohort and one patient in the 400-mg BID plus predni-
solone cohort whose current dose of orteronel was reduced 
to 200 mg BID with prednisolone 5 mg BID.
Demographic and other baseline characteristics are 
shown in Table 1. The overall median age was 71.0 years. 
All 15 patients experienced relapses and had a baseline 
ECOG performance status of 0. Gleason scores at the time 
Table 1  Demographic and other baseline characteristics
Orteronel
All subjects (N = 15)
Sex—n (%)
 Male 15 (100)
Age—years
 n 15
 Mean (SD) 69.5 (4.90)
 Median 71.0
 Min, max 60, 77
Gleason classification score at the time of the latest examination— 
n (%)
 ≤6 0 (0)
 7 1 (7)
 8 4 (27)
 9 7 (47)
 10 3 (20)
Histological type—n (%)
 Adenocarcinoma 14 (93)
 Well differentiated 0 (0)
 Moderately differentiated 3 (20)
 Poorly differentiated 10 (67)
 Unclassified 1 (7)
 Other 1 (7)
TNM classification—n (%)
 T3N0M0 2 (13)
 T3N0M1 2 (13)
 T3N1M0 2 (13)
 T3N1M1 2 (13)
 T3N1MX 1 (7)
 T4N0M1 2 (13)
 T4N1M1 3 (20)
 TXN0M1 1 (7)
Eastern cooperative oncology group (ECOG) performance status— 
n (%)
 0 15 (100)
 1 or 2 0 (0)
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of the latest examination were 7 or more for all patients. 
All patients received prior medication for prostate cancer, 
and two patients (13 %) received other prior therapies for 
prostate cancer including radiation to prostate gland in one 
patient and palliative radiation to lumbar vertebrae metasta-
sis and bilateral orchidectomy in one patient.
The median duration of treatment days across the 
cohorts was 276.0 days, and the treatment duration was 
shorter in the 400-mg BID cohort (60.0 days) than in the 
other cohorts (Table 2). All 15 patients completed Cycle 1 
treatment at the prescribed dose and were eligible for DLT 
assessment.
Safety results
The treatment-emergent AEs (TEAEs) that occurred in 
≥10 % of patients during the study are shown in Table 3. 
Neither DLTs nor serious AEs (SAEs) were reported in 
Cycle 1 in any cohort. Overall, all 15 patients (100 %) 
experienced at least 1 TEAE, and 14 patients (93 %) 
experienced at least 1 treatment-related AE. Most com-
mon TEAEs that were observed in >30 % of patients were 
hyperlipasemia, hyperamylasemia, and constipation.
No deaths were reported in this study. Nine patients 
(60 %) experienced a total of 14 SAEs, of which nine were 
considered to be related to the study treatment. No treat-
ment-related SAE was observed in the 200- and 300-mg 
BID cohorts. Acute pancreatitis was reported in two patients 
(400-mg BID cohort and 400-mg BID plus prednisolone 
cohort) and resulted in permanently discontinuation of orte-
ronel. Other treatment-related SAEs reported in one patient 
each were diabetes mellitus, gastric ulcer hemorrhage, 
hyperamylasemia, hyperlipasemia, interstitial lung disease, 
pneumonitis, and pyrexia. We had two experiences of the 
elevation of pancreatic enzymes in 400-mg BID cohort. First 
one was observed on Day 60. The patient had complaint of 
continuous abdominal discomfort. Laboratory data of amyl-
ase and lipase were elevated. Slight peripancreatic effu-
sion was pointed out by abdominal CT scan. The signs and 
symptom were diagnosed as acute pancreatitis. After discon-
tinuation of orteronel, the symptom and abnormal data were 
resolved. Second one was asymptomatic and checked in 
some laboratory data including amylase and lipase as moni-
toring. The patient had Grade 3 hyperamylasemia and Grade 
4 hyperlipasemia with unremarkable pancreatic change by 
CT scan. Afterward, we added the periodical monitoring of 
Table 2  Exposure to orteronel
a
 Relative dose intensity = (total dose received/total dose expected per initial dose) × 100
Orteronel
200 mg (N = 3) 300 mg (N = 3) 300 mg +  
prednisolone  
(N = 3)






 n 3 3 3 3 3 15
 Mean (SD) 597.0 (307.44) 342.7 (129.07) 172.3 (92.32) 61.0 (24.52) 397.3 (311.21) 314.1 (260.51)
 Median 420.0 399.0 142.0 60.0 499.0 276.0
 Min, max 419, 952 195, 434 99, 276 37, 86 48, 645 37, 952
Total amount of doses taken (103 mg)
 n 3 3 3 3 3 15
 Mean (SD) 227.4 (133.89) 171.5 (63.49) 86.9 (49.69) 36.7 (8.93) 156.1 (131.92) 135.7 (103.74)
 Median 167.4 156.2 82.5 35.0 133.0 133.0
 Min, max 134, 381 117, 241 40, 139 29, 46 37, 298 29, 381
Relative dose intensitya in cycle 1 (%)
 n 3 3 3 3 3 15
 Mean (SD) 100.00 (0.000) 100.00 (0.000) 99.80 (0.344) 95.24 (8.248) 100.00 (0.000) 99.01 (3.681)
 Median 100.00 100.00 100.00 100.00 100.00 100.00
 Min, max 100.0, 100.0 100.0, 100.0 99.4, 100.0 85.7, 100.0 100.0, 100.0 85.7, 100.0
Relative dose intensitya during study (%)
 n 3 3 3 3 3 15
 Mean (SD) 93.21 (11.650) 85.96 (18.311) 82.34 (15.212) 79.22 (15.894) 65.77 (36.373) 81.30 (20.331)
 Median 99.88 92.63 83.70 72.92 74.65 83.70
 Min, max 79.8, 100.0 65.2, 100.0 66.5, 96.8 67.4, 97.3 25.8, 96.9 25.8, 100.0
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pancreatic enzymes in this protocol after these events. The 
onset of abnormal pancreatic enzymes was reported during 
early treatment phase (around Cycle 2 or Cycle 3). In most 
patients, these abnormal elevations were reported without 
any symptom or radiographic abnormalities in pancreas. 
Three conditions were diagnosed as acute pancreatitis or 
pancreatitis in this study. Other two pancreatitis were also 
reported in 400-mg BID cohort with or without prednisolone 
(Grades 1 and 2). In 300-mg BID orteronel with or without 
prednisolone cohorts, pancreatitis was not reported. A total 
of ten patients experienced pancreatic-related AEs. Two 
patients were recovered from the abnormality without any 
dose change of orteronel. Other three patients were rechal-
lenged with orteronel after the pancreatic enzyme returned 
to normal. Of these three patients, two continued treatment 
without any experience of pancreas-related TEAEs. Another 
patient experienced a re-elevation of pancreatic enzyme, but 
pancreatitis was not complicated.
Mineralocorticoid-related TEAEs such as hyperten-
sion (n = 4) and hypokalemia (n = 3) were mild, and the 
Table 3  Subject incidence of treatment-emergent adverse events by preferred term in descending order of frequency (≥10 % subjects in all sub-
jects during the study, any Grade and Grade 3 or higher)
Adverse events were coded using the MedDRA version 13.0




200 mg (N = 3) n 
(%)
300 mg (N = 3) n 
(%)
300 mg + predniso-
lone (N = 3) n (%)
400 mg (N = 3) n 
(%)
400 mg + predniso-
lone (N = 3) n (%)
All subjects 
(N = 15) n (%)
Any 
grade























 Number of 
subjects
3 (100) 1 (33) 3 (100) 3 (100) 3 (100) 3 (100) 3 (100) 2 (67) 3 (100) 3 (100) 15 (100) 12 (80)
 Hyperlipa-
semia
– – 3 (100) 3 (100) 3 (100) 2 (67) 1 (33) 1 (33) – – 7 (47) 6 (40)
 Hyperamyla-
semia
– – 2 (67) 1 (33) 3 (100) 1 (33) 1 (33) 1 (33) – – 6 (40) 3 (20)
 Constipation – – – – 2 (67) – – – 3 (100) – 5 (33) –




1 (33) – 1 (33) – – – 1 (33) – 1 (33) – 4 (27) –
 Hypertension 1 (33) – 1 (33) 1 (33) – – 2 (67) – – – 4 (27) 1 (7)
 Malaise – – – – 1 (33) – 2 (67) – 1 (33) – 4 (27) –
 Hypokalemia – – – – – – 3 (100) 1 (33) – – 3 (20) 1 (7)
 Nasopharyn-
gitis
1 (33) – – – – – – – 2 (67) – 3 (20) –
 Nausea – – 1 (33) – – – 1 (33) – 1 (33) – 3 (20) –
 Rash – – – – – – – – 3 (100) – 3 (20) –
 Abdominal 
pain upper
– – – – – – 1 (33) – 1 (33) – 2 (13) –




1 (33) – – – 1 (33) – – – – – 2 (13) –
 Contusion – – – – – – 1 (33) – 1 (33) – 2 (13) –
 Diabetes mel-
litus
– – – – 1 (33) 1 (33) – – 1 (33) – 2 (13) 1 (7)
 Fall – – – – – – – – 2 (67) – 2 (13) –
 Insomnia 1 (33) – – – – – – – 1 (33) – 2 (13) –
 Pancreatitis 
acute
– – – – – – 1 (33) – 1 (33) 1 (33) 2 (13) 1 (7)
 Pneumonia – – – – 1 (33) – – – 1 (33) 1 (33) 2 (13) 1 (7)
 Vomiting – – – – – – 1 (33) – 1 (33) – 2 (13) –
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symptoms were manageable without dose reduction or 
dose hold of orteronel except for one Grade 3 hypokalemia. 
All patients who experienced these events were enrolled in 
prednisolone-free cohort. No TEAE associated with adre-
nal insufficiency was reported in this study.
No Grade 3 or higher abnormalities were observed in 
hematologic test or urinalysis. No clinically significant 
abnormal 12-lead ECG and echocardiography findings 
were observed either in any patient or at any assessment 
point during the study.
PK results
The maximum plasma concentration (Cmax) of ortero-
nel was observed at approximately 1–3 h after the morn-
ing dose on Day 8 of Cycle 1 in all cohorts (Table 4). The 
plasma concentrations of orteronel increased with the BID 
dosing in all cohorts and the cumulative ratios of area 
under the plasma concentration–time curve (AUC) on Day 
8 ranged from 1.10 to 1.67. Dose-dependent increases in 
Cmax and AUC of orteronel on Day 8 were indicated in the 
dose range of the 200 and 400 mg BID. Differences in the 
values of PK parameters between prednisolone-free and 
prednisolone coadministration were not clearly observed 
at orteronel doses of 300 and 400 mg BID. The time to 
achieve Cmax (Tmax) of M-I on Day 8 was approximately 
3–8 h in all cohorts. AUC of M-I on Day 8 was approxi-
mately 30–50 % of that of orteronel in each cohort. The 
fractional urinary excretion rates for 24 h after the morning 
dose on Day 15 ranged from 36 to 47 % of the dose for 
orteronel and from 14 to 21 % of the dose for M-I, indicat-
ing that more than half of the oral dose was excreted into 
urine in all cohorts.
PD and antitumor effects
The endocrine parameters are presented in Table 5. Serum 
testosterone was suppressed to LLOQ or lower by 1 week 
after the initiation of orteronel treatment (Day 8) across all 
cohorts. Serum DHEA-S was also suppressed by ortero-
nel on Day 8. The mean level of serum DHEA-S on Day 8 
was lower in 400 mg BID of orteronel than lower dose of 
orteronel. In addition, the levels in prednisolone-coadmin-
istration cohorts were lower than those in corresponding 
prednisolone-free cohorts.
The overall median maximum PSA reduction was 
88.48 % during the study. Of 15 PSA-evaluable patients, 13 
(87 %) achieved at least a 50 % reduction from baseline in 
PSA. With regard to objective disease responses based on 
the General Rule for Clinical and Pathological Studies on 
Prostate Cancer, no patient had a best response of complete 
response (CR) and five patients had a best response of par-
tial response (PR). The objective response rate (CR + PR) 
was 33 % (5/15 patients). Regarding objective disease 
responses based on modified RECIST version 1.0, only 
six patients had measurable disease. No patient had a best 
response of CR or PR.
Discussion
A total of 15 patients were treated by orteronel at doses of 
200, 300, 300 mg BID plus prednisolone, 400, and 400 mg 
BID plus prednisolone. Orteronel was well tolerated at 
doses up to 400 mg BID in Japanese CRPC patients either 
as a single agent or in combination with prednisolone. No 
DLTs were reported during the DLT assessment period in 
any cohort. PSA responses and testosterone levels indicated 
the potential clinical efficacy of orteronel with or without 
prednisolone coadministration.
The small amount of remaining androgens after castra-
tion for prostate cancer plays an important role in the prolif-
eration of prostate tumor cells. Abiraterone was developed 
as an androgen production inhibitor [11]. To prevent min-
eralocorticoid excess syndrome and adrenal insufficiency, 
prednisolone is required to coadminister with abiraterone. 
Orteronel selectively inhibits 17,20-lyase and may offer 
benefits compared with other therapies that target andro-
gen synthesis, with a reduced need for concurrent admin-
istration of steroids (prednisolone). In contrast, high dose 
of orteronel may block 17-hydroxylase activity, thereby 
resulting in increased mineralocorticoid activity in patients 
not receiving concomitant glucocorticoids. Thus, mineralo-
corticoid excess syndrome (hypertension and hypokalemia) 
and adrenal insufficiency-related TEAEs were assessed as 
significant AEs in this study.
Consequently, as mineralocorticoid excess syndrome-
related TEAEs, hypertension, and hypokalemia were 
reported. Both events were observed in the prednisolone-
free cohorts, and most patients who experienced these 
events received high dose (400 mg BID) of orteronel. 
These patients except one did not require dose reduction or 
dose hold, and their symptoms were manageable by treat-
ment with eplerenone and other agents. No adrenal insuffi-
ciency-related TEAEs were reported in any cohorts. These 
results suggest that concomitant administration of predni-
solone (5 mg BID) may not be required for preventing min-
eralocorticoid excess syndrome-related TEAEs, especially 
in lower doses of orteronel (200 or 300 mg BID). Pancre-
atic enzyme abnormalities were observed with relatively 
high frequencies. Such changes were asymptomatic in most 
patients, who did not display the evidence of pancreatitis 
in diagnostic imaging. In the study, increases in pancre-
atic enzyme levels were intensively reported in Cycles 2 
and 3, and these abnormalities subsequently returned to 
normal without dose change or after dose discontinuation 
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of orteronel. Although some patients resumed orteronel 
after recovering from the abnormality, no one complicated 
acute pancreatitis by rechallenge of orteronel. The patients 
who received orteronel for a long period did not exhibit an 
abnormal pancreatic enzyme in the late treatment phase 
(Day 150 or later), suggesting that increases in pancreatic 
enzyme levels occurred in the early treatment phase of 
orteronel, and that the possibility of delayed and/or recur-
rent increases is relatively low. In the case of asymptomatic 
elevation of pancreatic enzymes, the abnormalities were 
reversible by dose hold of orteronel, and the orteronel treat-
ment could be resumed with or without dose reduction. 
Although the mechanism(s) of the increases in pancreatic 
enzymes is unclear, it is possible that orteronel causes 
drug-induced pancreatic hyperenzymemia rather than pan-
creatitis similarly as other drugs such as sorafenib [16]. We 
need to further discuss the relationship between increase in 
pancreatic enzyme and in pancreatitis.
Tmax of orteronel was approximately 1–3 h after oral 
administration, and more than half of the oral dose was 
excreted into urine in all cohorts. M-I was considered 
to be a primary metabolite of orteronel, judging from 
the AUC ratio of M-I to orteronel and the urinary excre-
tion rate of M-I. These findings indicated that orteronel is 
well absorbed after oral administration, and absorbed orte-
ronel is primarily metabolized into M-I as well as urinary 
excretion. The comparison of the values of PK parameters 
between prednisolone-free and prednisolone coadminis-
tration suggested no remarkable effect of coadministered 
prednisolone (5 mg) on the PK of orteronel.
Serum testosterone was rapidly suppressed to the 
LLOQ or lower across all cohorts, suggesting the expected 
Table 4  Pharmacokinetic parameters of orteronel and M-I on Day 8 of Cycle 1
n = 3, median (min, max) for Tmax, mean (SD) for other parameters
AUC0–8h: area under the plasma concentration–time curve from 0 to 8 h post-dose, Cmax: maximum plasma concentration, pred: 5 mg predniso-
lone, R (AUC): AUC0–8h [Day 8]/AUC0–8h [Day 1], Tmax: time to Cmax
PK parameter Cohort
200 mg BID 300 mg BID 300 mg + pred BID 400 mg BID 400 mg + pred BID
Orteronel
 Tmax 1.00 (1.00, 2.92) 3.00 (2.00, 7.75) 3.00 (2.00, 5.00) 2.97 (2.95, 2.98) 2.00 (1.08, 3.00)
 Cmax (μg/mL) 1.58 (0.38) 3.10 (1.0) 3.19 (0.42) 4.70 (1.3) 5.96 (2.1)
 AUC0–8h (h μg/mL) 7.64 (2.1) 14.5 (4.5) 16.7 (1.4) 28.6 (11) 30.7 (11)
 R (AUC) 1.58 (0.62) 1.10 (0.17) 1.67 (0.33) 1.46 (0.42) 1.66 (0.13)
M-I
 Tmax 2.92 (2.00, 5.00) 7.75 (5.00, 8.00) 4.98 (3.00, 5.00) 4.83 (2.98, 4.93) 3.00 (2.75, 5.00)
 Cmax (μg/mL) 0.478 (0.25) 0.885 (0.27) 1.25 (0.21) 1.37 (0.37) 1.47 (0.67)
 AUC0–8h (h μg/mL) 3.17 (1.5) 5.29 (1.2) 7.97 (2.0) 9.02 (1.6) 9.83 (4.2)
Table 5  Summary statistics of endocrine panel
The lower limits of quantification (LLOQ) are: testosterone 0.05 and 0.03 ng/dL, DHEA-S 2.0 μg/dL. Testosterone assay was changed during 
the study, making LLOQ changed from 0.05 to 0.03 ng/mL
A cycle was defined as a 4-week (28-day) period
DHEA-S dehydroepiandrosterone sulfate
Assessment (unit) visit Orteronel
200 mg (N = 3) 300 mg (N = 3) 300 mg + prednisolone 
(N = 3)
400 mg (N = 3) 400 mg + prednisolone 
(N = 3)
Testosterone (ng/mL)
 Screening Mean (SD) 0.153 (0.0611) 0.123 (0.0702) 0.127 (0.0473) 0.057 (0.0115) 0.053 (0.0058)
 Cycle 1 Day 8 Mean (SD) 0.050 (0.0000) 0.030 (0.0000) 0.030 (0.0000) 0.050 (0.0000) 0.043 (0.0115)
 Cycle 2 Day 1 Mean (SD) 0.050 (0.0000) 0.030 (0.0000) 0.030 (0.0000) 0.050 (0.0000) 0.037 (0.0115)
DHEA-S (μg/dL)
 Screening Mean (SD) 114.7 (8.96) 146.7 (79.83) 136.0 (52.68) 60.3 (8.50) 40.3 (7.57)
 Cycle 1 Day 8 Mean (SD) 25.0 (7.21) 23.3 (14.57) 6.3 (4.16) 9.3 (0.58) 2.3 (0.58)
 Cycle 2 Day 1 Mean (SD) 30.0 (9.64) 24.3 (11.93) 2.3 (0.58) 19.3 (16.29) 2.0 (0.00)
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pharmacological effects by orteronel in Japanese CRPC 
patients. Serum DHEA-S, which is the upstream hormone 
of testosterone synthesis, was also suppressed by ortero-
nel administration. The reduction in serum DHEA-S levels 
appeared to depend on the orteronel dosage or concurrent 
administration of prednisolone. However, because of the sen-
sitivity of hormone assays and degree of variability among 
patients, no significant differences were found in endocrine 
responses between the 300- and 400-mg BID orteronel. Due 
to the small number of patients in this study, it may require 
further evaluation to determine whether 300- or 400-mg BID 
orteronel is recommended for Japanese CRPC patients.
Mean and median reductions in PSA were evaluated dur-
ing the study. However, the number of patients was too small 
to draw meaningful conclusions regarding the dose. The com-
pliance of 2 PSA non-responders to orteronel dosing was 
sufficient during the study according to their relative dose 
intensities (96.8 and 83.7 %, respectively), and their serum 
testosterone and DHEA-S concentrations were suppressed to 
the LLOQ or lower. It has been reported that a certain type 
of prostate cancer cells grows in a testosterone-independent 
manner [17], and thus, the 2 PSA non-responders may have 
developed a testosterone-independent type of prostate cancer.
In conclusion, orteronel at doses up to 400 mg BID was 
tolerable in Japanese CRPC patients. The results of the pre-
sent study support further evaluation of orteronel with or 
without prednisolone.
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